Time for Action: The Financial Crisis and Biotech SMEs

25.09.2009

Small and Medium-sized Enterprises (SMEs) are the creators of innovative biotech products and processes. The current financial crisis is effectively cutting the flow of capital to these companies. Losing this lifeblood will have significant repercussions – both the competitiveness of the EU and the future of the biotech industry as a whole will suffer if we do not find a way to secure investment in biotech innovation, a sector which has been identified by the EU as key to leading Europe’s  economic recovery.

 

Latest Position papers